PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased announce ...
A combination of the personalized cancer vaccine intismeran autogene and Merck's Keytruda just barely cleared analysts’ ...
AbbVie is eyeing regulatory filings in 2027 for the skin disease drug lutikizumab after clearing multiple endpoints in a late ...
The oral drug reduced DUX4 in FSHD patient muscle cells and increased lean mass and muscle power in a human study ...
In the Phase 3 INTREPID study, lutikizumab achieved the primary endpoint of Hidradenitis Suppurativa Clinical Response 75 ...
These honors underscore Cepheid's continued focus on helping healthcare providers deliver A Better Way through timely ...
Antogen, Inc., a biotechnology company pioneering next-generation personalized diagnostics through immunopeptidomics, today ...
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company’s Board of ...
Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced the appointment of Chadi ...
SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating ...
BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced a clinical trial collaboration and supply agreement with Gilead ...
At the European Society for Medical Oncology meeting this weekend, Merck will showcase three late-stage trials of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results